

Technology Advisory Interests Register

Topic: Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]

Publication Date: TBC

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Peter Wheatley-Price	TAC Committee Member	Direct	Takeda manufacture Bevacizumab is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and, if RAS wildtype and medically appropriate, an anti-EGFR therapy.	05/11/2025	It was agreed that Peter's declaration would prevent them from participating in discussions on this Appraisal
Steven Clark	Expert	Direct - Financial	Director of Redwood Brand Curators, a consultancy firm that works with the pharmaceutical industry. I can confirm that the company has not worked with any companies in the oncology field. The company is in discussion with one pharmaceutical company to potentially advise on patient engagement for a product for use before colonoscopy (bowel prep).	05/11/2025	It was agreed that Steven Clark's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
		Direct – non-financial	<ul style="list-style-type: none"> • Founder of a not for profit, Strive for Five, which aims to bring hope to people with stage 4 cancer, and advocates for improvements in care. • Volunteer Campaigns Ambassador for Cancer Research UK. • Volunteer patient forum member for Bowel Matters / Bowel Cancer Support Group UK. • Volunteer group expert for Bowel Cancer UK's Living with Stage 4 Facebook group. • Member of the International Society for Patient Engagement Professionals. • Member of the Pharmaceutical Marketing Society. • Member of Independent Cancer Patients Voice. • Patient Advocate Member of the Global Colon Cancer Association. 		

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
			<ul style="list-style-type: none"> • Patient Advocate Member of the European Society of Medical Oncology. 		
Richard Adams	Expert	Direct – financial	BMS conference fees and speaker fees TAKEDA advisory role TEYSUNO advisory role SERVIER conference fees and speaker fees GSK advisory role and speaker fees	05/11/2025	It was agreed that Richard Adams' declaration would not prevent them from providing expert advice to the committee
Mark Saunders	Expert	Direct – non-financial	Clinical advisor for EAG for this appraisal.	05/11/2025	It was agreed that Mark Saunders' declaration would not prevent them from providing expert advice to the committee

DRAFT